Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess

被引：14
作者：
Ciccolini, J. [1 ]
Barbolosi, D. [1 ]
Andre, N. [1 ,2 ]
Benzekry, S. [3 ]
Barlesi, F. [4 ]
机构：
[1] Aix Marseille Univ, Canc Res Ctr Marseille, SMARTc, INSERM U1068, Marseille, France
[2] La Timone Univ Hosp Marseille, Pediat Hematol & Oncol Dept, Marseille, France
[3] Bordeaux Inst Math, MONC Team, INRIA, Bordeaux, France
[4] La Timone Univ Hosp Marseille, INCa Labelled Early Phases Ctr CLIP2, Marseille, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷 / 11期
关键词：
D O I：
10.1093/annonc/mdz297
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1690 / 1691
页数：3
相关论文
共 13 条
[1]  
[Anonymous], [No title captured]
[2]   Computational oncology - mathematical modelling of drug regimens for precision medicine [J].
Barbolosi, Dominique ;
Ciccolini, Joseph ;
Lacarelle, Bruno ;
Barlesi, Fabrice ;
Andre, Nicolas .
NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (04) :242-254
[3]   Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients [J].
Barlesi, Fabrice ;
Imbs, Diane-Charlotte ;
Tomasini, Pascale ;
Greillier, Laurent ;
Galloux, Melissa ;
Testot-Ferry, Albane ;
Garcia, Melanie ;
Elharrar, Xavier ;
Pelletier, Annick ;
Andre, Nicolas ;
Mascaux, Celine ;
Lacarelle, Bruno ;
El Cheikh, Raouf ;
Serre, Raphael ;
Ciccolini, Joseph ;
Barbolosi, Dominique .
ONCOTARGET, 2017, 8 (29) :47161-47166
[4]   Combinations of Bevacizumab With Cancer Immunotherapy [J].
Chen, Daniel S. ;
Hurwitz, Herbert .
CANCER JOURNAL, 2018, 24 (04) :193-204
[5]   Chemoimmunotherapy: reengineering tumor immunity [J].
Chen, Gang ;
Emens, Leisha A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (02) :203-216
[6]   Combining conventional therapy with immunotherapy: A risky business? [J].
Coosemans, A. ;
Vankerckhoven, A. ;
Baert, T. ;
Boon, L. ;
Ruts, H. ;
Riva, M. ;
Blagden, S. ;
Delforge, M. ;
Concin, N. ;
Mirza, M. R. ;
Ledermann, J. A. ;
du Bois, A. ;
Vergote, I .
EUROPEAN JOURNAL OF CANCER, 2019, 113 :41-44
[7]  
Grothey A, ESMO 2018 C 2018
[8]   Revisiting dosing regimen using PK/PD modeling: the MODEL1 phase I/II trial of docetaxel plus epirubicin in metastatic breast cancer patients [J].
Henin, Emilie ;
Meille, Christophe ;
Barbolosi, Dominique ;
You, Benoit ;
Guitton, Jerome ;
Iliadis, Athanassios ;
Freyer, Gilles .
BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (02) :331-341
[9]   Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial [J].
Reck, Martin ;
Mok, Tony S. K. ;
Nishio, Makoto ;
Jotte, Robert M. ;
Cappuzzo, Federico ;
Orlandi, Francisco ;
Stroyakovskiy, Daniil ;
Nogami, Naoyuki ;
Rodriguez-Abreu, Delvys ;
Moro-Sibilot, Denis ;
Thomas, Christian A. ;
Barlesi, Fabrice ;
Finley, Gene ;
Lee, Anthony ;
Coleman, Shelley ;
Deng, Yu ;
Kowanetz, Marcin ;
Shankar, Geetha ;
Lin, Wei ;
Socinski, Mark A. .
LANCET RESPIRATORY MEDICINE, 2019, 7 (05) :387-401
[10]   Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity [J].
Seliger, Barbara .
FRONTIERS IN IMMUNOLOGY, 2019, 10
12